Treatment of precocious puberty in two patients with Turner mosaicism.
Turner's syndrome (TS) is clinically characterized by reduced growth, ovarian dysgenesis and infertility. The majority of patients with TS do not undergo spontaneous pubertal development. We report two patients with mosaic Turner karyotype who experienced precocious pubertal development. The first patient responded well to LHRH analog treatment and now has regular menses and has nearly achieved her target height. The second patient was treated with both LHRH analog and recombinant growth hormone. LHRH analog delayed puberty for the patient and the recombinant growth hormone increased the patient's predicted height from 145 cm to 158 cm. This report emphasizes that the treatment goals and modalities of patients must be tailored to the individual to optimize pubertal and growth outcomes.
Evanchec
Kimberly A
KA
Saint Vincent College, Latrobe, PA, USA.
Rotenstein
Deborah
D
D002648:Child; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D007621:Karyotyping; D011629:Puberty, Precocious / Q000188:drug therapy* / Q000235:genetics*; D016896:Treatment Outcome; D014424:Turner Syndrome / Q000150:complications* / Q000235:genetics
D007987:Gonadotropin-Releasing Hormone